Sector
PharmaceuticalsOpen
₹1,613.85Prev. Close
₹1,646.75Turnover(Lac.)
₹2.98Day's High
₹1,613.85Day's Low
₹1,613.8552 Week's High
₹1,749.6552 Week's Low
₹472.05Book Value
₹607.13Face Value
₹10Mkt Cap (₹ Cr.)
487.91P/E
25.89EPS
62.27Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 3.02 | 3.02 | 3.02 | 3.02 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 161 | 148.19 | 123.31 | 110.23 |
Net Worth | 164.02 | 151.21 | 126.33 | 113.25 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 260.25 | 256.92 | 344.15 | 212.98 |
yoy growth (%) | 1.29 | -25.34 | 61.58 | -1.34 |
Raw materials | -139.65 | -162.04 | -230.28 | -132.95 |
As % of sales | 53.66 | 63.07 | 66.91 | 62.42 |
Employee costs | -27.11 | -23.27 | -20.63 | -17.64 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 19.35 | 13.33 | 23.75 | 6.39 |
Depreciation | -7.21 | -7.24 | -5.76 | -5.7 |
Tax paid | -6.18 | -4.19 | -7.12 | 0.1 |
Working capital | 6.73 | 5.63 | 4.3 | 1.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 1.29 | -25.34 | 61.58 | -1.34 |
Op profit growth | 25 | -26.72 | 145.88 | -53.6 |
EBIT growth | 29.45 | -36.93 | 176.29 | -57.05 |
Net profit growth | 43.95 | -45 | 155.84 | -49.77 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 305.96 | 315.56 | 349.74 | 265.59 | 260.78 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 305.96 | 315.56 | 349.74 | 265.59 | 260.78 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 3.83 | 5.42 | 14.76 | 1.78 | 2.28 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,862.95 | 160.6 | 4,46,984.11 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,479.35 | 87.57 | 1,45,452.89 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,659.4 | 33.75 | 1,34,027.85 | 1,055.94 | 0.78 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,453.9 | 77.74 | 1,16,844.73 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,115.85 | 25.7 | 1,12,260.5 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
T V V S N Murthy
Independent Director
P Sarath Kumar
Company Sec. & Compli. Officer
Trupti Ranjan Mohanty
Executive Director
Talluri Venkata Praveen
Whole-time Director
Sudeepthi Gopin eedi
Independent Director
Mannam Malakondaiah
Independent Director
Srinivas Samavedam
Independent Director
P Venkata Subbarao
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by SMS Lifesciences India Ltd
Summary
The Company was incorporated originally as Potluri Real Estate Private Limited on 31May, 2006 for undertaking the activities of real estate business and the Company could not commence business activities andthe companys name has been changed to Potluri Packaging Industries Private Limited on 6 November, 2013. The Company could not undertake any such activities, once again the companys name has been changed to SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company has become a wholly owned subsidiary company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016. Subsequently converted into a Public Company under the Companies Act, 2013 w.e.f. 22 June, 2016.The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad.The Demerger Scheme sanctioned by the National Company Law Tribunal (NCLT) vide its order dated 15-05- 2017 received by the Company on 17-05-2017 has been implemented with appointed date as 01st April, 2016 as provided in the Scheme. Accordingly, the Semi Regulated Facilities i.e., Unit I, IV and V along with (i) premises situated at Industrial Estate, Sanath Nagar, Hyderabad; (ii) Industrial Development area, Jeedimetla, Hyderabad; (iii) Flat No. 417, Nilgiri, Aditya Enclave, Ameerpet, Hyderabad and (iv) Vacant Land admeasuring Ac 19.00 situated at Pharma
Read More
The SMS Lifesciences India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1613.85 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Lifesciences India Ltd is ₹487.91 Cr. as of 13 Sep ‘24
The PE and PB ratios of SMS Lifesciences India Ltd is 25.89 and 2.77 as of 13 Sep ‘24
The 52-week high/low is the highest and lowest price at which a SMS Lifesciences India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of SMS Lifesciences India Ltd is ₹472.05 and ₹1749.65 as of 13 Sep ‘24
SMS Lifesciences India Ltd's CAGR for 5 Years at 27.69%, 3 Years at 29.04%, 1 Year at 200.26%, 6 Month at 158.43%, 3 Month at 95.84% and 1 Month at 21.10%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice